Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.34 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18668999 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2MAPK1MAPTHSD17B10TYR | |
| SCHEMBL22206203 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2MAPK1MAPTHSD17B10TYR | |
| SCHEMBL23331939 | 0.83 | ACHE (0.43) | SMN1; SMN2MAPK1MAPTHSD17B10TYR | |
| SCHEMBL18686238 | 0.83 | MAPT (0.37) | SMN1; SMN2MAPTHSD17B10EPHX2PLA2G2A | |
| SCHEMBL18668921 | 0.83 | PLA2G2C (0.38) | MAPTHSD17B10PLA2G2APLA2G5TSHR | |
| SCHEMBL18686282 | 0.83 | PLA2G2C (0.38) | MAPTHSD17B10PLA2G2APLA2G5TSHR | |
| SCHEMBL3729786 | 0.82 | CTSK (0.51) | CTSBCTSK | |
| SCHEMBL18668909 | 0.82 | CTSK (0.51) | CTSBCTSK | |
| SCHEMBL13039839 | 0.82 | CTSK (0.51) | CTSBCTSK | |
| SCHEMBL24938388 | 0.82 | SMN1; SMN2 (0.37) | SMN1; SMN2MAPK1MAPTHSD17B10TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115803017-A | Pharmaceutical granulation of water-soluble active pharmaceutical ingredients | 凯瑞康宁生物工程有限公司 | 2023-03-14 | — | — | CN | claimed |
| CN-115038432-A | Controlled release granulation of water soluble active pharmaceutical ingredients | 凯瑞康宁生物工程（武汉）有限公司 | 2022-09-09 | — | — | CN | claimed |
| US-20220183977-A1 | CONTROLLED RELEASE GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | XWPharma Ltd. (KY) | 2022-06-16 | — | — | US | claimed |
| US-11304906-B2 | Controlled release granulations of water-soluble active pharmaceutical ingredients | XWPharma Ltd. (KY) | 2022-04-19 | — | — | US | claimed |
| US-20210393529-A1 | CONTROLLED RELEASE GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | XWPharma Ltd. (KY) | 2021-12-23 | — | — | US | claimed |
| US-20210393537-A1 | PHARMACEUTICAL GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | XWPharma Ltd. (KY) | 2021-12-23 | — | — | US | claimed |
| US-10774031-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | XW LABORATORIES INC. (KY) | 2020-09-15 | — | — | US | claimed |
| US-20200223783-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XW LABORATORIES INC. (KY) | 2020-07-16 | — | — | US | claimed |
| US-20250262157-A1 | CONTROLLED RELEASE GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | XWPharma Ltd. (KY) | 2025-08-21 | — | — | US | disclosed |
| US-12337066-B2 | Controlled release granulations of water-soluble active pharmaceutical ingredients | XWPharma Ltd. (KY) | 2025-06-24 | — | — | US | disclosed |
| CN-117618393-A | Controlled release granulation of water-soluble active pharmaceutical ingredient | 凯瑞康宁生物工程（武汉）有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-115038432-B | Controlled release granulation of water-soluble active pharmaceutical ingredient | 凯瑞康宁生物工程（武汉）有限公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-115803017-A | Pharmaceutical granulation of water-soluble active pharmaceutical ingredients | 凯瑞康宁生物工程有限公司 | 2023-03-14 | — | — | CN | disclosed |
| US-20220323366-A1 | PHARMACEUTICAL GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | XWPharma Ltd. (KY) | 2022-10-13 | — | — | US | disclosed |
| US-10774031-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | XW LABORATORIES INC. (KY) | 2020-09-15 | — | — | US | disclosed |
| US-20200223783-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XW LABORATORIES INC. (KY) | 2020-07-16 | — | — | US | disclosed |
| US-10640451-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | XW LABORATORIES INC. (KY) | 2020-05-05 | — | — | US | disclosed |
| US-10457627-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | XW LABORATORIES INC. (KY) | 2019-10-29 | — | — | US | disclosed |
| US-20190218168-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2019-07-18 | — | — | US | disclosed |
| US-20190194120-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10640451-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | GABRB3, GABRB2, GABRB1 | SMN1; SMN2 2384/4885MAPK1 4712/4885MAPT 3453/4885 |
| US-12337066-B2 | Controlled release granulations of water-soluble active pharmaceutical ingredients | GMPS, SI, UGGT1 | SMN1; SMN2 3927/4885MAPK1 4614/4885MAPT 2661/4885 |
| US-20210393529-A1 | CONTROLLED RELEASE GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | GMPS, SI, UGGT1 | SMN1; SMN2 3927/4885MAPK1 4614/4885MAPT 2661/4885 |
| US-20250262157-A1 | CONTROLLED RELEASE GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | GMPS, SI, UGGT1 | SMN1; SMN2 3927/4885MAPK1 4614/4885MAPT 2661/4885 |
| US-10457627-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | GABRB3, GABRB2, GABRB1 | SMN1; SMN2 2384/4885MAPK1 4712/4885MAPT 3453/4885 |
| US-20190194120-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | GABRB3, GABRB2, GABRB1 | SMN1; SMN2 2384/4885MAPK1 4712/4885MAPT 3453/4885 |
| US-20220323366-A1 | PHARMACEUTICAL GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | GMPS, GYS2, SLC18A1 | SMN1; SMN2 3367/4885MAPK1 4181/4885MAPT 2638/4885 |
| US-10774031-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | GABRB3, GABRB2, GABRB1 | SMN1; SMN2 2384/4885MAPK1 4712/4885MAPT 3453/4885 |
| US-20210393537-A1 | PHARMACEUTICAL GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | GMPS, GYS2, SLC18A1 | SMN1; SMN2 3367/4885MAPK1 4181/4885MAPT 2638/4885 |
| US-20220183977-A1 | CONTROLLED RELEASE GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | GMPS, SI, UGGT1 | SMN1; SMN2 3927/4885MAPK1 4614/4885MAPT 2661/4885 |
| US-11304906-B2 | Controlled release granulations of water-soluble active pharmaceutical ingredients | GMPS, SI, UGGT1 | SMN1; SMN2 3927/4885MAPK1 4614/4885MAPT 2661/4885 |
| US-20190218168-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | GABRB3, GABRB2, GABRB1 | SMN1; SMN2 2384/4885MAPK1 4712/4885MAPT 3453/4885 |
| US-20200223783-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | GABRB3, GABRB2, GABRB1 | SMN1; SMN2 2384/4885MAPK1 4712/4885MAPT 3453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.